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Background: Human leukocyte antigen-G (HLA-G) molecules play a prominent role in
immune tolerance. Structurally similar to their classical HLA homologs, they are distinct
by having high rate of polymorphism in the non-coding regions including a functionally
relevant 14-base pair (bp) insertion/deletion (Ins/Del) allele in the 3′ untranslated region
(3′UTR), rarely examined in a hematopoietic stem cell transplantation (HSCT) setting. Here,
we analyzed the potential impact of HLA-G Ins/Del dimorphism on the incidence of acute
graft-versus-host disease (aGvHD), transplant-relatedmortality (TRM), overall survival (OS),
and incidence of relapse after HSCT using bone marrow (BM) as stem cell source from
HLA-matched donors.Methods:One hundred ﬁfty-seven sibling pairs, who had undergone
HSCT, were studied for the distribution of the HLA-G 14bp Ins/Del polymorphism using a
polymerase chain reaction (PCR)-based technique. Potential genetic association with the
incidence of aGvHD,TRM, and OS was analyzed by monovariate and multivariate analyses.
Results: Monovariate analysis showed that the homozygous state for the 14-bp Ins allele
is a risk factor for severe aGvHD (grade III and IV; P= 0.008), conﬁrmed subsequently
by multivariate analysis [hazard ratio (HR)= 3.5; 95% conﬁdence interval (95%CI)= 1.3–
9.5; P= 0.012]. We did not ﬁnd any association between HLA-G polymorphism and the
other studied complications. Conclusion:Our data suggest that the HLA-G low expressor
14 bp Ins allele constitutes a risk factor for the incidence of severe aGvHD in patients who
received BM as stem cell source.
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INTRODUCTION
In hematopoietic stem cell transplantation (HSCT), substantial
advances in conditioning regimens, prophylactic measures and
treatments of post-transplant complications have been made
in combination with an improved donor/recipient (D/R) HLA
genetic proﬁling. Despite such progresses, impending, and unpre-
dictable severity of acute graft-versus-host disease (aGvHD),
remains a major complication (Dickinson and Charron, 2005;
Messina et al., 2008; Socié and Blazar, 2009). Consequently, much
attention has been focused on genetic mechanisms that govern the
Abbreviations: 95%CI, 95% conﬁdence interval; BMT, bone marrow transplan-
tation; bp, base pair; CMV, cytomegalovirus; CTL, cytotoxic T lymphocyte; CYA
A, cyclosporine A; Del, deletion; D/R, donor/recipient; EBV, epstein-barr-virus;
GvHD, graft-versus-host disease; HLA, human leukocyte antigen; HR, hazard
ratio; HSCT, hematopoietic stem cell transplantation; Ins, insertion; MHC, major
histocompatibility complex; MTX, methotrexate; NK, natural killer; OS, over-
all survival; PBSC, peripheral blood stem cells; PCR, polymerase chain reac-
tion; TRM, transplant-related mortality; UD-BMT, unrelated-donor bone marrow
transplantation.
transplant tolerance. Among the pivotal actors of such immuno-
modulation, the human leukocyte antigen-G (HLA-G) molecules
are of great interest because of their various immunosuppres-
sive/immune tolerogenic properties such as, inhibition of both
natural killer (NK) cytotoxicity (Rouas-Freiss et al., 1997) and
antigen-speciﬁc cytotoxic CD8+T cell (CTL) functions (Wiendl
et al., 2002) as well as CD4+T cell allogeneic proliferation
(Bainbridge et al., 2000).
Belonging to the non-classicalHLA-class Ib family and encoded
by a locusmapped telomeric toHLA-Agene, theHLA-Gmolecules
are structurally similar to their classical counterparts, yet are dis-
tinct by the following characteristics: limited tissue distribution in
physiological conditions, diversity of isoforms generated by alter-
native splicing, i.e., four membrane-bound (HLA-G1 to -G4) and
three soluble (HLA-G5 to -G7) isoforms (sHLA-G; Paul et al.,
2000) and unique pattern of polymorphisms in the non-coding
regions especially within the promoter and the 3′-untranslated
region (3′UTR; Larsen and Hviid, 2009). As identiﬁed to date,
HLA-G gene presents a limited number of exonic polymorphisms
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with 46 alleles accounting for 15 protein variants (IMGT/HLA
Sequence Database1). Each of these alleles bears either a 14-base
pair (bp) insertion (Ins) or deletion (Del) polymorphism in the 3′
UTR which inﬂuences the HLA-G expression. Indeed, the inser-
tion allele (+14 bp), albeit initially described to improve HLA-G
mRNA stability (O’Brien et al., 2001; Hviid et al., 2003; Rousseau
et al., 2003), was subsequently demonstrated to be associated
with low levels of HLA-G mRNA and serum sHLA-G isoforms
(Chen et al., 2008; Rizzo et al., 2008) with likely consequences on
functional properties of HLA-G molecules.
Given such genotype-dependant phenotype expression status,
studies have focused on the HLA-G dimorphism in various clin-
ical settings including gestational complications, auto-immunity,
infections, cancers, and solid organ transplantation (Larsen and
Hviid, 2009). In a HSCT setting, three studies have addressed the
potential role of HLA-G in the development of post-transplant
complications (La Nasa et al., 2007; Le Maux et al., 2008; Chiu-
solo et al., 2011), two exploring the 14-bp dimorphism-related
diversity and one evaluating the pre- and post-transplant level of
sHLA-G molecules, both in relation with the incidence of aGvHD.
However, conducted on small sample size of D/R cohorts, in differ-
ent HSCT study design, these studies generated conﬂictory data
regarding the role of HLA-G in HSCT outcomes. To clarify the
issue, in this retrospective study, we have analyzed the HLA-G
14 bp Ins/Del polymorphism in a large cohort of patients who
have undergone HSCT in relation with aGvHD, transplant-related
mortality (TRM), relapse, and overall survival (OS).
MATERIALS AND METHODS
STUDY POPULATION
One hundred ﬁfty-seven consecutive patients who underwent
non-T-cell depleted allogeneic HSCT were included in this study.
All of them received bone marrow (BM) from HLA-identical sib-
ling donors as stem cell source andwere recruited between January
1995 and January 2004 in the BM Transplant Department of
Saint-Louis Hospital, Paris, France. It is of interest to note that
136 patients (87%) were transplanted for hematological malig-
nant disorders. The detailed characteristics of D/R pairs are given
in Table 1. The supportive therapy as well as the criteria used to
deﬁne the outcomes namely aGvHD, TRM, and OS were as pre-
viously detailed in a study involving a part of the present cohort
(Rocha et al., 2002). It is important to precise that the main out-
come, aGvHD, was deﬁned according to modiﬁed Glucksberg’s
criteria (Glucksberg et al., 1974; Przepiorka et al., 1995). The vast
majority of patients (144/157, 92%) received the same GvHD pro-
phylaxis protocol with cyclosporineA (CYAA) and pulsed doses of
methotrexate (MTX). Informed consent was obtained according
to the declaration of Helsinki.
HLA-G GENOTYPING
Both donors and recipients were tested for HLA-G genotype.
GenomicDNAwas extracted fromEDTA-treated peripheral blood
samples using the standard salting out procedure (John et al.,
1991). The 14-bp Ins/Del polymorphism (rs 66554220) in the
1http://www.ebi.ac.uk/imgt/hla/
Table 1 | Patients, disease, and transplant characteristics.
Characteristics n=157
RECIPIENTS
Median age, years 28.4
Male (%) 91 (58%)
Children, 15 year or younger (%) 39 (25%)
Positive CMV serology (%) 94 (60%)
HLA-G
14 Heterozygote 76 (48%)
14− Homozygote 49 (31%)
14+ Homozygote 32 (21%)
Underlying diagnosis
Chronic leukemia (%) 31 (20%)
Acute leukemia (%) 80 (51%)
Other malignant disorders (%) 25 (16%)
Non-malignant disorder 21 (13%)
Disease status for malignant disorders
Early (%) 107 (79%)
Intermediate (%) 13 (10%)
Advanced (%) 15 (11%)
DONORS
Median age 29.9
Male (%) 83 (53%)
Female donor to male recipient (%) 43 (27%)
ABO major incompatibility (%) 24 (15%)
Positive CMV serology (%) 80 (51%)
HLA-G
14 Heterozygote 76 (48%)
14− Homozygote 49 (31%)
14+ Homozygote 32 (21%)
TRANSPLANTATION
GVHD prophylaxis
CYA A 5 (3%)
CYA A+MTX 144 (92%)
CYA A+others 3 (2%)
Conditioning
TBI-based 60 (38%)
Bu-based 97 (62%)
CMV, cytomegalovirus; CYA A, cyclosporin A; MTX, methotrexate;TBI, total body
irradiation; Bu, Busulfan.
exon 8 encoding the HLA-G 3′ UTR was genotyped as previously
described (Tripathi et al., 2004). Brieﬂy, after polymerase chain
reaction (PCR), ampliﬁed products were size-discriminated by
agarose gel electrophoresis with appropriate controls of known
HLA-G genotypes that had previously been characterized by
nucleotide sequencing. Alleles having the 14-bp sequence in exon
8 was termed HLA-G 14pb Ins whereas those without, HLA-G
14pb Del.
STATISTICAL ANALYSIS
Differences in categorical variables between the two groups were
evaluated by Chi-square analysis. Since HLA-G genotypes are
identical among patients and donors, the predictive effect of recip-
ient genotype (HLA-G 14 bp Ins/Ins, 14 bp Ins/Del, and 14 bp
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Del/Del) was assessed as variable. Cumulative incidence using
competing risk method, as described by Fine and Gray (1999),
was used for the assessment of prognostic factors of acute GvHD
(grades II–IV or grades III–IV) with death as a competing event.
The Cox regression (stepwise backward procedure) analysis and
competing risk regression were used in multivariate analysis of
independent risk factors of GvHD (Cox, 1972). Similar methodol-
ogy was used to analyze the other outcomes namely TRM, relapse,
and OS. All tests were two-sided, with type I error rate ﬁxed at
0.05. Statistical analyses were performed with SPSS 15 software,
Stata 11, and R packages “cmprsk” (competing risks). D/R pairs
as well as transplant-related characteristics such as disease stage,
D/R age, and sex as well as cytomegalovirus (CMV) serology sta-
tus that could potentially inﬂuence the post-HSCT outcomes were
evaluated in all pairs and were included in multivariate analysis.
RESULTS
The sibling D/R pairs were fully matched for HLA-G genotypes
with the following frequencies: HLA-G 14 bp Ins/Ins: 21%, HLA-
G 14 bp Ins/Del: 48%, and HLA-G 14 bp Del/Del: 31% which were
comparable to those previously reported2
In the studied sample, 71 patients (45%) developed a grade II to
IV acute GvHD at day 100. Among them, 15 patients (21%) expe-
rienced the severe form (grade III and IV). Monovariate analysis
using competing risk showed that the homozygous state of the
HLA-G14 bp Ins/Ins genotypewasmore prevalent amongpatients
who experienced aGvHD (grade 0, I versus II, III, IV), but failed
to reach statistical signiﬁcance (P = 0.06; Figure 1). Nevertheless
additional monovariate analysis after patient stratiﬁcation based
on aGvHD severity (grade 0, I, II versus III, IV) revealed a sig-
niﬁcant association between the HLA-G 14 bp Ins/Ins genotype
and severe aGvHD (HLA-G 14 bp Ins/Ins versus others: 22% ver-
sus 6%; P = 0.008; Figure 2). These data were further conﬁrmed
using two different multivariate analysis adjusted for confounding
variables (gender,CMV status, age of recipient, and disease status).
The only factor that remained statistically signiﬁcant was HLA-G
14 bp Ins/Ins genotype; [hazard ratio (HR)= 3.26; 95% conﬁ-
dence interval (95%CI)= 1.16–9.14; P = 0.024 by Cox regression
and HR= 3.5; (95%CI)= 1.3–9.5; P = 0.012 by competing risk
regression]. Given the potential effect of methotrexate (MTX) on
HSCT outcome in the context of HLA-G polymorphism (Chiu-
solo et al., 2011), we re-analyzed the sub-group who received this
drug for aGvHD prophylaxis (n = 144). We found no changes in
the above-mentioned association,but rather strengthened and this
is despite a reduction in the sample size [P = 0.001 and HR= 4.7;
(95%CI)= 1.5–3.15; P = 0.009 in monovariate and multivariate
analyses respectively].
We did not ﬁnd any other relationship between HLA-G geno-
type and the other complications explored in this study (TRM,
relapse, and OS; data not shown).
DISCUSSION
Inappropriate immune responses are often the substratum
of immune disorders including those related to the preven-
tion/treatment of the underlying disease per se. A typical example
2http://www.ncbi.nlm.nih.gov/.
FIGURE 1 | Cumulative incidence for aGvHD following BMT based on
HLA-G recipient genotype (grade 0, I versus II, III, IV).
FIGURE 2 | Cumulative incidence for aGvHD based on HLA-G genotype
in patients stratified for severity (grade 0, I, II versus III, IV).
of such process is represented by the post-HSCT aGvHD. GvHD
results from a sequential activation of both D/R immune cells
allowing overwhelming of inﬂammation with consequent tissue
damage (Reddy and Ferrara, 2003; Ferrara et al., 2009; Socié and
Blazar,2009). It is evident that understanding themolecularmech-
anisms that could lead to induction of immune tolerance may
provide clues for novel therapeutic management. In such context,
given the prominent role of HLA-G molecules in immune toler-
ance, we focused our attention on the genetics of this locus to
clarify the inter-patient differences in the incidence and severity
of aGvHD in a HSCT setting.
Indeed, studying a functionally relevant HLA-G gene polymor-
phism, namely the HLA-G 14 bp Ins/Del variation, we found that
the presence of the HLA-G 14 Ins/Ins genotype increased the risk
of developing severe aGvHD in patients transplanted with BM
as the stem cell source. These ﬁndings are in line with the data
provided by other studies in different clinical settings including
gestational complications, auto-immunity, infections, cancers as
well as solid organ transplantation (Larsen and Hviid, 2009). This
polymorphic variation in HLA-G seems to inﬂuence the RNA
splicing stability by mechanisms that are yet to be understood.
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The presence of 14-bp insertion, introducing an additional splice
site, results in the removal of the ﬁrst 92 bp of exon 8 generat-
ing more stable HLA-G mRNAs species than the complete mRNA
(O’Brien et al., 2001; Hviid et al., 2003; Rousseau et al., 2003).
In fact, the 3′ UTR 14 bp insertion have been consistently asso-
ciated with low expression of HLA-G mRNA and low serum
sHLA-G (Chen et al., 2008; Rizzo et al., 2008). Such a discrepancy
between stability and output, termed “the 14-bp polymorphism
paradox” (Veit and Chies, 2009), predicts complex mechanisms
of regulation of HLA-G expression. Recent studies implicate the
potential role of microRNAs which by interacting with the HLA-
G 3′ mRNA region, may regulate its phenotype expression (Veit
and Chies, 2009; Castelli et al., 2010). Indeed, a C to G poly-
morphic change at position+ 3142 of the 3′ UTR (rs1063320)
has been identiﬁed as a putative binding site for three microR-
NAs (miR-148a, miR-148b, and miR-152) and functional studies
demonstrate that the 3′ UTR+ 3142 G allele favors binding of
these microRNAs with consequent down regulation of HLA-G
expression (Tan et al., 2007). In addition, presence of an adenine at
position+ 3187 (rs 9380142), in the close vicinity of an (AU)-rich
motif, was also found to be associated with diminished stability
of HLA-G mRNA species both in in silico and in vitro experi-
ments (Yie et al., 2008). Interestingly, the two above-mentioned
variant alleles, one affecting the mRNA translation and the other
affecting the mRNA stability, are found to be in strong linkage
disequilibrium with the HLA-G 14 bp Ins allele in independent
studies involving various population groups (Tan et al., 2007;
Castelli et al., 2010; Larsen et al., 2010). The observed effect of
Ins allele on aGvHD could be either due to the above-mentioned
combined effect (haplotype effect) or due to another yet to be
identiﬁed linked functional variant. A recent study associated the
14-bp Ins/+ 3142G/+ 3187A haplotype with the risk to develop
pre-eclampsia, amultisystemic complication of pregnancy (Larsen
et al., 2010).
Our data on the effect of the insertion allele in the incidence
of aGvHD ﬁt perfectly within the concept that a downregulated
expression of HLA-G molecules could decrease their immunosup-
pressive/tolerogenic properties with consequent aGvHD develop-
ment. They are also in concordance with the data showing that
high pre- and post-transplantation levels of sHLA-G molecules
correlate not only with a decreased incidence of aGvHD but also
with a high frequency of circulating regulatory T-cells (Treg; Le
Maux et al., 2008). Similar correlation between sHLA-G and Treg
cells was also observed in in vitro mixed leukocyte reaction assay
(Le Maux et al., 2008), in the context of liver transplantation
(Le Rond et al., 2006) and in a transgenic murine model system
(Ristich et al., 2007).
Our ﬁndings are also in agreement with the majority of expres-
sion studies of HLA-G in solid organ transplantation evidencing
the beneﬁcial effect of HLA-G molecules against acute rejec-
tion/chronic dysfunction of the transplanted heart and kidney
(Lila et al., 2000, 2002; Crispim et al., 2008a) and also with those
establishing correlations between the presence of theHLA-G 14 bp
Ins allele and organ rejection (Crispim et al., 2008b; Piancatelli
et al., 2009; Twito et al., 2011).
In the overall context of transplantation, the only controversy
noted in the literature has been in associationwithHSCT outcome
(LaNasa et al., 2007;Chiusolo et al., 2011). Indeed, in one study, the
authors found that the aGvHD risk was associated with the HLA-
G 14 bp Del/Del genotype (La Nasa et al., 2007) which appears
to be in contradiction with the established fact that the 14-bp
Del allele is associated with higher levels of sHLA-G than the
14-bp Ins allele. Nevertheless, it must be noted that this study
concerned a relatively small cohort of D/R pairs (n = 53) and
moreover HLA-matched unrelated-donor (UD) HSCT in the con-
text of a non-malignant disorder, namely beta-thalassemia. The
mechanism of aGvHD could however be different in this situa-
tion. For example, since the HLA-matched unrelated D/R pairs
are not identical by descent, it could be possible that the HLA-G
14pb Del/Del genotype may reﬂect the MHC non-HLA haplo-
type disparity (Petersdorf et al., 2007). More recently, another
work involving 47 HSCT patients with a variety of hematological
malignancies failed to observe any signiﬁcant association between
the HLA-G 14 bp Ins/Del polymorphism and aGvHD (Chiusolo
et al., 2011), but found that patients homozygous for the 14-bp Ins
allele were characterized by a lower survival rate and disease free
survival. The authors related their ﬁndings to the possible relation-
ship between the HLA-G 14 bp dimorphism, methotrexate-based
aGvHD prophylaxis, and HLA-G expression. Possibly in line with
this, our ﬁnding of positive association with aGvHD was not
altered by the stratiﬁcation of our patients based on their aGvHD
prophylaxis.
It must also be stressed that the herein studied cohort of HSCT
patients was homogeneous with respect to the donor stem cell
source, namely BM derived stem cells. In this context, it is of
interest to note that the main soluble HLA-G isoform, HLA-G5, a
recognized major inducer of regulatory T cell expansion, is specif-
ically expressed by erythroid progenitors residing within the BM
(Menier et al., 2004).
HSCT is a sensitive in vivo setting capable of revealing ﬁne
immune response traits, undetectable in physiological situations.
This is the plausible reason why the effect of Ins/Ins HLA-G geno-
type on conferring low immune tolerance has been uncovered in
this study.
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